Cost & insurance
GLP-1 Insurance Coverage and Prior Authorization: A Realistic Guide
Last clinically reviewed: July 20, 2026 by Dr. Prajeet Reddy, MD (Medical Director)

Weight management medications (also called anti-obesity medications, or AOMs) are FDA-approved treatments for people with obesity or overweight with related health conditions. Despite strong medical evidence supporting their use, many insurance plans — including Medicare, Medicaid, and some employer-sponsored plans — have historically limited or excluded coverage for these medications.[1] This guide explains how the coverage process really works, what to expect from prior authorization, and your options if coverage is denied.
What Is Prior Authorization?
Prior authorization (sometimes called "pre-authorization" or "PA") is a process where your doctor's office must get approval from your insurance company before a medication is covered. For weight management medications, this typically involves:
- Your doctor submitting documentation of your diagnosis (such as your BMI and any weight-related health conditions like diabetes, high blood pressure, or sleep apnea)
- Proof that you have tried lifestyle changes (diet and exercise)
- Sometimes, proof that you have tried other, less expensive medications first ("step therapy")
Prior authorization can take several days to weeks. Your doctor's office handles this process, but you may be asked to provide information or follow up with your insurance company. If a prior authorization is denied, your doctor can file an appeal. In Medicare Part D plans, prior authorization requirements for GLP-1 medications rose from below 5% through 2023 to nearly 100% by 2025.[2][3]
Medicare Coverage: What You Need to Know
Historically, Medicare Part D has not covered medications prescribed solely for weight loss. This exclusion dates back to a 2003 provision in the law that created the Part D benefit.[4][5] However, Medicare may cover certain medications if they are prescribed for another approved condition, such as:
- Type 2 diabetes (e.g., Ozempic, Mounjaro, Rybelsus)
- Cardiovascular risk reduction in patients with established heart disease and obesity/overweight (e.g., Wegovy)
- Obstructive sleep apnea in patients with obesity (e.g., Zepbound)[5]
Important: Medicare beneficiaries are generally not eligible for manufacturer discount cards or coupons.[1][6]
The Medicare BALANCE Program and GLP-1 Bridge Program
In 2026, the Centers for Medicare & Medicaid Services (CMS) launched a new program called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health). This program is designed to expand access to newer weight management medications — specifically GLP-1 and related medications — for Medicare and Medicaid beneficiaries.[7]
Key details of the BALANCE program:
- A short-term Medicare "bridge program" began in July 2026, administered directly by CMS
- Eligible Medicare Part D beneficiaries can access covered weight management medications for a co-pay of $50 per month
- The program uses standardized coverage criteria, which may simplify the prior authorization process
- Eligible medications must be FDA-approved for weight management, be a GLP-1 or related type of medication, and have clinical trial evidence showing an average of 10% or greater body weight reduction
- The program includes a lifestyle support component — manufacturers are required to provide resources to help with healthy eating, physical activity, and staying on your medication[7]
Research from the U.S. Department of Veterans Affairs suggests that removing financial barriers to access promotes medication adherence to levels similar to those seen in clinical trials.[7]
To find out if you qualify for the BALANCE bridge program, talk to your doctor's office or call 1-800-MEDICARE.
Private Insurance Coverage
Coverage for weight management medications varies widely among private insurance plans. Some plans cover these medications with prior authorization, while others exclude them entirely. If you have private insurance:
- Call the member services number on your insurance card to ask about coverage for your specific medication
- Ask your doctor's office to submit a prior authorization if coverage is available
- If denied, ask your doctor about filing an appeal
- You may be eligible for manufacturer savings cards that can lower your co-pay (see below)[6]
Medicaid Coverage
Medicaid coverage for weight management medications varies by state. Some states cover these medications, while others do not. Some states have dropped coverage due to high costs and unsuccessful pricing negotiations with drug manufacturers. Contact your state Medicaid office or ask your doctor's office for details.
Options If You Don't Have Coverage
If your insurance does not cover your weight management medication, there are several options to explore:
Manufacturer Savings Programs (Private Insurance Only)
- Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) offer savings cards for eligible patients with private insurance that can significantly reduce monthly costs[6]
- In 2023, patients used manufacturer co-payment cards for 63% of brand-name prescriptions to treat obesity
- These programs are not available to patients with Medicare, Medicaid, or other government insurance
- Visit the manufacturer's website or ask your doctor's office for details
Patient Assistance Programs
- Some manufacturers offer free or reduced-cost medication to patients who meet income-based eligibility requirements
- Organizations like NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain lists of available programs
- These programs are available across public and private insurance, though options for uninsured patients may be more limited[6]
Lower-Cost Medication Alternatives
- Phentermine is the least expensive FDA-approved weight management medication, often available for under $20 per month. It is approved for short-term use but is sometimes prescribed for longer periods. Ask your doctor if this is appropriate for you.[1][8]
- Phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) are other FDA-approved options that may be more affordable than GLP-1 medications[8]
- Metformin, while not FDA-approved specifically for weight loss, is very inexpensive and is sometimes used off-label for weight management
- Generic orlistat (Alli) is available over the counter
Oral Formulations
- An oral tablet form of semaglutide (Wegovy) was recently approved for weight management, which may offer different pricing or coverage options in the future
Approximate Monthly Costs Without Insurance
These are estimated wholesale costs and may vary by pharmacy:[8]
| Medication | Approximate wholesale cost |
|---|---|
| Phentermine | $15–$20/month |
| Phentermine-topiramate (Qsymia) | $115–$120/month |
| Naltrexone-bupropion (Contrave) | $640/month |
| Orlistat (prescription strength) | $680/month |
| Liraglutide (Saxenda) | $900/month |
| Semaglutide injection (Wegovy) | $900/month |
| Tirzepatide injection (Zepbound) | $1,080/month |
With manufacturer coupons and discounts, costs for GLP-1 medications can be lowered to approximately $7,000 to $8,000 per year for eligible patients with private insurance. Prices may also be lower with online pharmacy discount programs or manufacturer cash-pay programs.[6] Always verify prices at your pharmacy.
Tips for Navigating the Process
- Ask your doctor which medication is right for you based on your health conditions, insurance coverage, and budget
- Be patient with the prior authorization process — it is a normal part of getting these medications covered
- If your prior authorization is denied, ask your doctor about appealing the decision or trying an alternative medication
- Keep records of all communications with your insurance company
- Ask your doctor's office about any available savings programs or patient assistance options
- These medications work best when combined with healthy eating and regular physical activity[7]
When to Contact Your Doctor's Office
- If you have questions about which medication is right for you
- If your insurance denies coverage and you want to explore alternatives
- If you are having side effects from your medication
- If you want to learn more about the Medicare BALANCE bridge program
Insurance coverage, medication costs, and program details may change. Always verify current information with your insurance company and doctor's office.
Frequently asked questions
What is prior authorization for GLP-1 medications?
A process where your doctor's office must get insurance approval before the medication is covered — typically requiring documentation of your BMI and weight-related conditions, proof you've tried lifestyle changes, and sometimes step therapy (trying cheaper medications first). It can take days to weeks, and in Medicare Part D plans, prior authorization requirements for GLP-1s rose from under 5% through 2023 to nearly 100% by 2025.
Does Medicare cover Wegovy or Zepbound for weight loss?
Historically no — Part D excluded weight-loss-only prescriptions. But Medicare may cover them for other approved uses (Wegovy for cardiovascular risk reduction, Zepbound for obstructive sleep apnea), and the 2026 CMS BALANCE bridge program now offers eligible Part D beneficiaries covered weight-management GLP-1s at a $50/month co-pay. Call 1-800-MEDICARE to check eligibility.
What if my insurance denies coverage?
Ask your doctor about filing an appeal first. Beyond that: manufacturer savings cards can significantly cut costs for patients with private insurance (not available with Medicare/Medicaid), income-based patient assistance programs exist (see needymeds.org or rxassist.org), and manufacturer cash-pay programs offer set pricing without insurance at all.
Are manufacturer savings cards available with Medicare?
No — patients with Medicare, Medicaid, or other government insurance are generally not eligible for manufacturer discount cards or coupons. Those programs are limited to patients with private insurance. Cash-pay manufacturer pricing and patient assistance programs remain options.
Sources
- Medications for Obesity: A Review — Gudzune & Kushner, JAMA 2024
- Medicare Part D Coverage and Costs for GLP-1 Receptor Agonists — JAMA 2025
- Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D — JAMA Network Open 2025
- Medicare Part D Coverage of Anti-Obesity Medications — J Gen Intern Med 2024
- Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists — JAMA Health Forum 2025
- Strategies to Help Patients Navigate High Prescription Drug Costs — JAMA 2024
- CMS BALANCE Model for Obesity — Implications for Patients and Clinicians — JAMA 2026
- Approach to Obesity Treatment in Primary Care: A Review — Yanovski & Yanovski, JAMA Internal Medicine 2024
This article is for education and does not replace your prescriber’s instructions or the FDA Medication Guide that comes with your medication. Clinical content reviewed by Dr. Prajeet Reddy, MD, Medical Director (Cyane Medical Group California PC).
$29/mo membership — the lowest in GLP-1 telehealth. No contracts.